LEP and obesity disorder: Future directions in medical therapies should be focused on neurochemicals and mediators that regulate food intake, such as agouti-related protein, leptin, neuropeptide Y5, dopamine 3, gut hormones such as GLP-1 agonists, ghrelin antagonist, cholecystokinin agonists, pancreatic hormones; amylin, pancreatic polypeptide analogous, 11-β-hydroxysteroid dehydrogenases inhibitors, diglyceride acyltransferase inhibitors, lipase inhibitors, as well as genetic targets that are associated with obesity [101, 106].